Pancreatic Cancer News and Research

RSS
Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
Stereotactic body radiotherapy appears to be safe, effective for some pancreatic cancer patients

Stereotactic body radiotherapy appears to be safe, effective for some pancreatic cancer patients

Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

Researchers reveal molecular steps that allow pancreatic cancer to spread to the liver

Obese people at greater risk of developing cancer

Obese people at greater risk of developing cancer

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Merck KGaA, Darmstadt, Germany granted FDA Fast Track designation for development of evofosfamide

Zetz Family PCRF, Johns Hopkins Medicine partner for pancreatic cancer research

Zetz Family PCRF, Johns Hopkins Medicine partner for pancreatic cancer research

Pancreatic cancer rates higher in countries with less sunlight

Pancreatic cancer rates higher in countries with less sunlight

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Oncolytics' REOLYSIN granted EMA Orphan Drug Designation for pancreatic cancer treatment

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Merrimack completes submission of MM-398 NDA for treatment of post-gemcitabine metastatic pancreatic cancer

Oncologists publish review of advanced clinical treatments for pancreatic cancer

Oncologists publish review of advanced clinical treatments for pancreatic cancer

Researchers uncover methylated DNA markers that may lead to noninvasive cancer screening

Researchers uncover methylated DNA markers that may lead to noninvasive cancer screening

AACR throws spotlight on the experience of Individualized Molecular Pancreatic Cancer Therapy trial

AACR throws spotlight on the experience of Individualized Molecular Pancreatic Cancer Therapy trial

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

New drug combination shows promise in patients with metastatic melanoma

New drug combination shows promise in patients with metastatic melanoma

New, cross-sector collaboration aims to discover clinical biomarker for pancreatic cancer

New, cross-sector collaboration aims to discover clinical biomarker for pancreatic cancer

Study suggests that pancreatic cancers harbor genetic alterations

Study suggests that pancreatic cancers harbor genetic alterations

Common cancers deform mitochondria to create conducive environment for tumor growth

Common cancers deform mitochondria to create conducive environment for tumor growth

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Myriad Genetics expands companion diagnostic collaboration with AstraZeneca

Drug-resistant E. coli outbreak linked to contaminated endoscopes in Washington state hospital

Drug-resistant E. coli outbreak linked to contaminated endoscopes in Washington state hospital

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

New work flow system may improve patient appointments, reduce time-consuming work

New work flow system may improve patient appointments, reduce time-consuming work

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.